New drug AKB-9090 takes first steps in human safety trial
NCT ID NCT07429006
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug, AKB-9090, in about 70 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, given through a vein, in either a single dose or multiple doses over time. The main goal is to check for side effects and changes in vital signs, lab tests, and heart activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigator Site #1
RECRUITINGAuckland, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults